Cross-validated risk scores adaptive enrichment (CADEN) design

11/03/2021
by   Svetlana Cherlin, et al.
0

We propose a Cross-validated ADaptive ENrichment design (CADEN) in which a trial population is enriched with a subpopulation of patients who are predicted to benefit from the treatment more than an average patient (the sensitive group). This subpopulation is found using a risk score constructed from the baseline (potentially high-dimensional) information about patients. The design incorporates an early stopping rule for futility. Simulation studies are used to assess the properties of CADEN against the original (non-enrichment) cross-validated risk scores (CVRS) design that constructs a risk score at the end of the trial. We show that when there exists a sensitive group of patients, CADEN achieves a higher power and a reduction in the expected sample size, in comparison to the CVRS design. We illustrate the application of the design in a real clinical trial. We conclude that the new design offers improved statistical efficiency in comparison to the existing non-enrichment method, as well as increased benefit to patients. The method has been implemented in an R package caden.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
07/03/2020

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

The existing cross-validated risk scores (CVRS) design has been proposed...
research
07/31/2020

Enhancing single-arm phase II trials by inclusion of matched control patients

When a novel treatment has successfully passed phase I, different option...
research
06/25/2022

A gated group sequential design for seamless Phase II/III trial with subpopulation selection

Due to the high cost and high failure rate of Phase III trials, seamless...
research
05/06/2023

How mature are survival data at the time of an interim analysis in a clinical trial with a survival outcome?

In a clinical trial with a survival outcome, an interim analysis is ofte...
research
04/29/2022

Bayesian Benefit Risk Analysis

The process of approving and assessing new drugs is often quite complica...
research
04/17/2020

Multiplicity for a Group Sequential Trial with Biomarker Subpopulations

Biomarker subpopulations have become increasingly important for drug dev...

Please sign up or login with your details

Forgot password? Click here to reset